ENANTA PHARMACEUTICALS INC Balance Sheet
ENTA|13 years of annual SEC 10-K data (FY2013-FY2025)
Shows total assets, cash and equivalents, receivables, property and equipment, total debt, and shareholders' equity across 13 fiscal years. All figures from audited SEC 10-K filings.
ENANTA PHARMACEUTICALS INC had $281M in total assets and $129M in shareholders' equity as of FY2025.
Based on SEC 10-K filings.
Key Data Points
- Low Piotroski F-Score: 2/9 (multiple financial health concerns)
- Altman Z-Score -0.48 (distress zone, below 1.8 threshold)
- High earnings quality (cash-backed earnings)
Data sourced from SEC EDGAR filings. Not investment advice.
| Item | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 | FY2016 | FY2015 | FY2014 | FY2013 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Cash & Equivalents | $32.3M | $37.2M | $85.4M | $44.0M | $57.2M | $87.1M | $51.2M | $63.9M | $21.7M | $30.7M | $8.9M | $10.5M | $6.8M |
| Accounts Receivable | $6.9M | $6.6M | $8.6M | $20.3M | $23.6M | $23.5M | $51.3M | $67.2M | $10.6M | $12.8M | $15.3M | $1.7M | $808.0K |
| Current Assets | $204.3M | $299.9M | $422.8M | $311.7M | $319.0M | $436.8M | $401.8M | $380.4M | $237.8M | $232.2M | $170.6M | $108.0M | $104.7M |
| PP&E (Net) | $35.4M | $32.7M | $11.9M | $6.2M | $5.9M | $8.6M | $10.9M | $8.4M | $8.0M | $8.0M | $5.9M | $1.8M | $1.1M |
| Total Assets | $280.7M | $376.7M | $462.3M | $375.4M | $438.8M | $486.1M | $489.8M | $414.2M | $326.6M | $281.3M | $246.0M | $155.4M | $117.0M |
| Current Liabilities | $48.6M | $57.5M | $62.8M | $29.8M | $36.2M | $24.2M | $22.6M | $16.0M | $21.0M | $7.9M | $6.7M | $4.7M | $4.5M |
| Shareholders' Equity | $128.8M | $321.3M | $399.4M | $455.6M | $462.5M | $393.7M | $301.7M | $269.9M | $236.2M | $148.7M | $110.5M | -$115.4M | -$132.0M |